FDA approves Biogen Idec’s ALPROLIX, the first Hemophilia B Therapy to reduce bleeding episodes with Prophylactic Infusions

31-03-2014 Business Wire HealthComments (0)

Biogen IdecBiotechnology

FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top